𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer

✍ Scribed by Marija Pastorcic-Grgic; Bozena Sarcevic; Danijel Dosen; Antonio Juretic; Giulio C. Spagnoli; Marko Grgic

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
184 KB
Volume
32
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

The prognostic value of cancer testis antigens in pharyngeal cancer is understudied.

Methods

We recruited 90 patients who were treated for pharyngeal cancer. Monoclonal antibodies 57B and B9.8.1.1 were used for detection of MAGE‐A and NY‐ESO‐1 genes.

Results

MAGE‐A and NY‐ESO‐1 gene products were detectable in 70.0% and 33.3% of pharyngeal tumors, respectively. No correlation was established between MAGE‐A and NY‐ESO‐1 expression and TNM staging at presentation. Survival analysis showed a trend toward a shorter 5‐year disease‐free survival in the group of patients with MAGE‐A–positive tumors (log‐rank test, p = .122). In contrast, a trend toward a prolonged 5‐year disease‐free survival was observed in the group of patients with NY‐ESO‐1–positive tumors (log‐rank test, p = .219).

Conclusion

In a large population of patients with pharyngeal cancer and available 5‐year survival data, prognosis tended to be poorer with MAGE‐A expression and better with NY‐ESO‐1 expression, but the correlations did not reach statistical significance. © 2009 Wiley Periodicals, Inc. Head Neck, 2010

📜 SIMILAR VOLUMES

Heterogeneous expression of GAGE, NY-ESO
Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy
✍ Argun Akcakanat; Tatsuo Kanda; Tadashi Tanabe; Shintarou Komukai; Kazuhito Yajim 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 421 KB

## Abstract Cancer/testis antigens (CTAs) elicit immune response in cancer patients and are therefore targets of immunotherapy. Current information on CTA expression is primarily based on mRNA assays and little is known about their expression at the protein level. The objectives of our study are to

NY-ESO-1/LAGE-1 coexpression with MAGE-A
NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: A tissue microarray study
✍ Martin Bolli; Elke Schultz-Thater; Paul Zajac; Ulrich Guller; Chantal Feder; Fra 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 165 KB

## Abstract The characterization of the expression pattern of different families of cancer/testis (C/T) antigens in different tumors, at the protein level, might be of relevance in the development of multiantigen vaccine preparations for active specific immunotherapy. We have used tissue microarray

High expression of cancer testis antigen
High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx
✍ David L. A. Figueiredo; Rui C. M. Mamede; Giulio C. Spagnoli; Wilson A. Silva Jr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 1 views

## Abstract ## __Background.__ Despite diagnostic and therapeutic advances in head and neck cancer, the 5‐year survival of patients with laryngeal cancer has not improved in the last 30 years. Several recent studies indicate that specific targets for immunotherapeutic approaches can be useful in t

Identification of NY-ESO-1, MAGE-1, and
Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma
✍ Matthew A. Kienstra; H. Bryan Neel; Scott E. Strome; Patrick Roche 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

## Abstract ## Background. Certain tumor antigens have been identified that stimulate an immune response, thus making them targets for immunotherapy. NY‐ESO‐1, MAGE‐1, and MAGE‐3 are such antigens. This study was undertaken to determine their presence or absence in head and neck squamous cell canc

Monophasic and biphasic synovial sarcoma
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-a1 or ct7
✍ Achim A. Jungbluth; Cristina R. Antonescu; Klaus J. Busam; Kristin Iversen; Deni 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 584 KB

Synovial sarcomas are high-grade malignant mesenchymal tumors with biphasic (BSS) and monophasic (MSS) variants that carry a pathognomonic cytogenetic alteration, t(X;18), involving the SYT gene on chromosome 18 and one of several SSX genes on chromosome X, usually SSX1 or SSX2. Cancer/ testis (CT)